Denali Therapeutics (DNLI) Enterprise Value (2017 - 2025)
Historic Enterprise Value for Denali Therapeutics (DNLI) over the last 9 years, with Q3 2025 value amounting to -$848.2 million.
- Denali Therapeutics' Enterprise Value fell 139.2% to -$848.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$848.2 million, marking a year-over-year decrease of 139.2%. This contributed to the annual value of -$832.3 million for FY2024, which is 1954.35% up from last year.
- Latest data reveals that Denali Therapeutics reported Enterprise Value of -$848.2 million as of Q3 2025, which was down 139.2% from -$899.0 million recorded in Q2 2025.
- Denali Therapeutics' 5-year Enterprise Value high stood at -$817.9 million for Q1 2025, and its period low was -$1.4 billion during Q1 2021.
- Moreover, its 5-year median value for Enterprise Value was -$1.0 billion (2023), whereas its average is -$1.0 billion.
- Over the last 5 years, Denali Therapeutics' Enterprise Value had its largest YoY gain of 4111.66% in 2021, and its largest YoY loss of 14063.82% in 2021.
- Quarter analysis of 5 years shows Denali Therapeutics' Enterprise Value stood at -$865.4 million in 2021, then plummeted by 54.4% to -$1.3 billion in 2022, then increased by 22.58% to -$1.0 billion in 2023, then grew by 19.54% to -$832.3 million in 2024, then dropped by 1.91% to -$848.2 million in 2025.
- Its last three reported values are -$848.2 million in Q3 2025, -$899.0 million for Q2 2025, and -$817.9 million during Q1 2025.